Model Medicines

Model Medicines is an AI-first biotechnology company that engineers first-in-class small molecules targeting biological choke points underlying disease, using its GALILEO end-to-end AI engine to design, discover, and develop pipeline-in-a-pill therapeutics. The platform utilizes AI-driven target discovery models to identify biological choke points central to multiple diseases, rapidly advancing validated assets through preclinical development. The company's pipeline includes two lead programs: RdRp Thumb-1, targeting a cryptic allosteric pocket on viral RNA-dependent RNA polymerase conserved across single-stranded RNA virus families, and BRD4, a transcriptional master regulator at the center of super-enhancer biology relevant to oncology, fibrosis, immunology, and cardiovascular disease. Lead assets MDL-001 and MDL-4102 address over 30 indications, with MDL-001 demonstrating broad-spectrum antiviral activity across six viral families. The company has published class-leading regulatory-grade toxicology models including AmesNet. Founded in 2019 and headquartered in San Diego, United States, the company has raised approximately $27.1 million at the Series A stage.